Clinical Trials Browser

Amyloidosis, Anemia, Bone Diseases, Metabolic, Fractures, Spontaneous, Hypercalcemia, Multiple Myeloma, Osteolysis, Paraproteinemias, Hematologic Neoplasms, Renal Insufficiency

NCT02632786 2019-04-05

PRONTO

Phase 2 Completed

129 enrolled 18 charts

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease, Amyloidosis, Paraproteinemias

NCT02791373 2018-04-03

ViGeM

Phase 2 Completed

136 enrolled

Plasma cell

Amyloidosis, Multiple Myeloma

NCT01677286 2017-08-01

Safety and Effect of Doxycycline in Patients With Amyloidosis

Phase 2 Completed

25 enrolled 13 charts

Plasma cell

AA amyloidosis, Immunoglobulin Light-chain Amyloidosis, Amyloidosis, Amyloidosis, Familial

NCT01194791 2017-04-25

LENDEXAL

Phase 2 Completed

30 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT00017680 2008-06-09

Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis

Phase 2 Completed

25 enrolled

Other hematologic neoplasmPlasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis, Arthritis, Connective Tissue Diseases, Hematologic Neoplasms, Genetic Diseases, Inborn, Rare Diseases, Neoplasms, Plasma Cell

Clinical Trials

Ixazomib Rollover Study

Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis

DUAL

Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

PRONTO

ViGeM

Safety and Effect of Doxycycline in Patients With Amyloidosis

LENDEXAL

Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis